Other research analysts have also issued research reports about the stock. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Goldman Sachs Group upped their price target on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Oppenheimer upped their price target on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Canaccord Genuity upped their price target on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the company a “positive” rating in a research note on Wednesday, November 20th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $71.38.
NASDAQ CRSP opened at $59.44 on Friday. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average price of $65.98 and a 200 day moving average price of $51.14. Crispr Therapeutics has a 52 week low of $28.95 and a 52 week high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, topping the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. As a group, equities analysts forecast that Crispr Therapeutics will post 0.65 EPS for the current year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the sale, the director now owns 7,500 shares in the company, valued at approximately $390,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock worth $3,620,760 over the last ninety days. Insiders own 21.40% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. BSW Wealth Partners purchased a new stake in Crispr Therapeutics during the second quarter worth $39,000. Balyasny Asset Management LLC purchased a new position in Crispr Therapeutics in the second quarter valued at $5,165,000. BNP Paribas Arbitrage SA purchased a new position in Crispr Therapeutics in the second quarter valued at $41,000. Bank of New York Mellon Corp increased its holdings in Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after buying an additional 17,810 shares in the last quarter. Finally, First Trust Advisors LP purchased a new position in Crispr Therapeutics in the third quarter valued at $987,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What are some reasons analysts would give stocks a buy rating?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.